Blockbuster year on the horizon

A handful of new agents with blockbuster potential recently approved by overseas jurisdictions hints at what's on the cards for Australia in 2023 - and into next year.

A recent Evaluate Vantage analysis shows the launch of six products - mostly in the US - is already underway, and there's no shortage of pending regulatory news for the remainder of the year, according to the analytics company.

While none are approved by the TGA, four are currently under the regulator's review, including Apellis Pharmaceuticals Syfovre, which won first-to-market for geographic atrophy. The complement factor C3 inhibitor is expected to reach US$2.3 billion in global sales by 2028, according to Evaluate.